Voltaren News and Research RSS Feed - Voltaren News and Research

Voltaren is a drug that is used to treat the symptoms of rheumatoid arthritis and is being studied in the prevention and treatment of some types of skin cancer. It blocks substances that cause inflammation and pain. It may also prevent the growth of new blood vessels that tumors need to grow. It is a type of cyclooxygenase inhibitor, a type of nonsteroidal anti-inflammatory drug (NSAID), and a type of antiangiogenesis agent. Also called diclofenac sodium.
Endo International revenues increase $719M to 1% in Q2 2014

Endo International revenues increase $719M to 1% in Q2 2014

Endo International plc today reported second quarter 2014 revenues of $719 million, an increase of 1 percent compared to second quarter 2013 revenues of $712 million. [More]
Endo Health Solutions Reports net loss of $776M in fourth quarter 2013

Endo Health Solutions Reports net loss of $776M in fourth quarter 2013

Endo Health Solutions today reported fourth quarter 2013 revenues of $585 million, compared to $750 million for the same quarter of 2012. [More]
Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

After nearly 13 years of study and intense debate, a pair of new papers from the Perelman School of Medicine, at the University of Pennsylvania have confirmed exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it. [More]
Endo fourth quarter total revenues increase 57% to $803.4 million

Endo fourth quarter total revenues increase 57% to $803.4 million

Endo Pharmaceuticals today reported financial results for the fourth quarter of 2011. [More]
Endo enters global development agreement with BDSI for BEMA Buprenorphine

Endo enters global development agreement with BDSI for BEMA Buprenorphine

Endo Pharmaceuticals announced today it has signed a worldwide license and development agreement with U.S.-based BioDelivery Sciences International for BEMA Buprenorphine. [More]
Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

Endo, BDSI partner to develop and commercialize BEMA Buprenorphine for chronic pain

BioDelivery Sciences International, Inc. today announced the signing of a worldwide license and development agreement with Endo Pharmaceuticals for the exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain. [More]
BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

BioLineRx, Tel Aviv University sign license agreement to develop and commercialize BL-7050

BioLineRx, a biopharmaceutical development company, today announced that it has signed a worldwide, exclusive license agreement with Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain. [More]
Cardium to purchase Transdel's business assets

Cardium to purchase Transdel's business assets

Cardium Therapeutics today announced that it had entered into an agreement with Transdel Pharmaceuticals to acquire substantially all of Transdel's business assets including a Phase 3 product candidate Ketotransdel (TDLP-110), which is a topically-administered analgesic for the treatment of musculoskeletal pain. [More]
Endo fourth quarter total revenues increase 31% to $511 million

Endo fourth quarter total revenues increase 31% to $511 million

Endo Pharmaceuticals today reported financial results for the fourth quarter 2010. [More]
Painkillers and heart attack risk

Painkillers and heart attack risk

A new study has shown that taking certain commonly used painkillers for long periods or in high doses increases the risk of heart attacks or strokes. The study comes from researchers from Bern University and is published in the British Medical Journal. [More]
Endo third quarter total revenues increase 23% to $444.1 million

Endo third quarter total revenues increase 23% to $444.1 million

Endo Pharmaceuticals today reported financial results for the third quarter 2010. [More]
Stroke risk with common pain killers dismissed by manufacturer

Stroke risk with common pain killers dismissed by manufacturer

An eight-year Danish study, which involved more than 2.5 million healthy Danes found there was a higher risk of stroke for those taking high doses of ibuprofen, which is in the painkiller Nurofen. The manufacturers of Nurofen, Reckitt Benckiser, have dismissed these reports. The spokesperson for the company said, “it is important to note that the conclusions drawn by the study authors are based on high doses of ibuprofen…The results of this study should not be confused with non-prescription low doses of NSAIDs, such as ibuprofen, which are available over-the-counter and used by millions of people around the world, for short periods of time, every day.” [More]
Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo Pharmaceuticals total revenues for second-quarter 2010 increase 6% to $396.5 million

Endo Pharmaceuticals today reported financial results for the second quarter 2010. Total revenues during the second quarter of 2010 increased 6 percent to $396.5 million, compared with $373.1 million in the same quarter of 2009. Net income for the three months ended June 30, 2010 was $51.5 million, compared with $30.0 million in the comparable 2009 period. [More]
Endo acquires HealthTronics

Endo acquires HealthTronics

Endo Pharmaceuticals announced today the completion of its acquisition of HealthTronics, Inc., a leading U.S. provider of urological products and services, located in Austin, Texas. [More]
Endo subsidiary successfully completes tender offer for HealthTronics' outstanding common stock

Endo subsidiary successfully completes tender offer for HealthTronics' outstanding common stock

Endo Pharmaceuticals today announced the successful completion of the tender offer by its wholly owned subsidiary, HT Acquisition Corp., for all of the outstanding shares of common stock of HealthTronics, Inc.. [More]
Endo responds to FDA Complete Response letter for FORTESTA NDA

Endo responds to FDA Complete Response letter for FORTESTA NDA

Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months. [More]
Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo, Penwest announce settlement of OPANA ER litigation with Impax

Endo Pharmaceuticals and Penwest Pharmaceuticals announced today that the companies have settled litigation with Impax Laboratories, Inc. regarding the production and sale of generic formulations of OPANA® ER (oxymorphone hydrochloride) Extended Release tablets. [More]
Endo Pharmaceuticals to acquire all outstanding shares of HealthTronics common stock

Endo Pharmaceuticals to acquire all outstanding shares of HealthTronics common stock

HealthTronics, Inc., a leading provider of urological products and services, today announced that it has signed a definitive merger agreement with Endo Pharmaceuticals pursuant to which Endo will acquire HealthTronics. [More]
Endo Pharmaceuticals signs agreement to acquire HealthTronics

Endo Pharmaceuticals signs agreement to acquire HealthTronics

Continuing to diversify, move into new growth areas beyond pharmaceuticals, and strengthen its commitment to improved patient outcomes in urology, Endo Pharmaceuticals today announced that it has signed an agreement to acquire HealthTronics, Inc., a leading U.S. provider of urological products and services. [More]
Endo Pharmaceuticals reports 9% increase in first-quarter 2010 revenues

Endo Pharmaceuticals reports 9% increase in first-quarter 2010 revenues

Endo Pharmaceuticals today reported financial results for the first quarter 2010. [More]